Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lundbeck

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lundbeck's 2013 CNS (central nervous system) sales performance.

FDA sets August review date for Teva's movement disorder drug

FDA sets August review date for Teva's movement disorder drug Huntington's disease is a much smaller market than TD but that has not stopped the only approved drug for the condition - Lundbeck's Xenazine (tetrabenazine) - bring in sales of $330m

Gilead Sciences appoints general manager, Canada

Gilead Sciences appoints general manager, Canada Prior to this, he was general manager for Gilead Nordic and Baltic and also brings experience from Lundbeck as general manager for Sweden.

Therachon strengthens management team

Therachon strengthens management team He most recently served as a senior director at Lundbeck, leading the Danish firm's global biologics programme to treat CNS diseases, and before this held senior roles at Amplimmune and

Lundbeck partners with IBM Watson on drug research

Lundbeck partners with IBM Watson on drug research Starting with projects in schizophrenia and Parkinson's disease, Lundbeck and IBM will also work together to identify potential new drug targets and alternative indications. ... the 425 million people who suffer from the psychiatric and neurological

Dr Irina Antonijevic joins vasopharm

Dr Irina Antonijevic joins vasopharm She brings over 15 years of global drug development experience in neuroscience to vasopharm, having held positions at Schering's German operations and Lundbeck Research in the US.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics